Literature DB >> 23539563

The role of nonsense-mediated decay in neuronal ceroid lipofuscinosis.

Jake N Miller1, Chun-Hung Chan, David A Pearce.   

Abstract

Neuronal ceroid lipofuscinosis (NCL), commonly referred to as Batten disease, is a group of autosomal recessive neurodegenerative diseases of childhood characterized by seizures, blindness, motor and cognitive decline and premature death. Currently, there are over 400 known mutations in 14 different genes, leading to five overlapping clinical variants of NCL. A large portion of these mutations lead to premature stop codons (PTCs) and are predicted to predispose mRNA transcripts to nonsense-mediated decay (NMD). Nonsense-mediated decay is associated with a number of other genetic diseases and is an important regulator of disease pathogenesis. We contend that NMD targets PTCs in NCL gene transcripts for degradation. A number of PTC mutations in CLN1, CLN2 and CLN3 lead to a significant decrease in mRNA transcripts and a corresponding decrease in protein levels and function in patient-derived lymphoblast cell lines. Inhibiting NMD leads to an increased transcript level, and where protein function is known, increased activity. Treatment with read-through drugs also leads to increased protein function. Thus, NMD provides a promising therapeutic target that would allow read-through of transcripts to enhance protein function and possibly ameliorate Batten disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23539563      PMCID: PMC4439521          DOI: 10.1093/hmg/ddt120

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  54 in total

1.  Nonsense-mediated translational repression involves exon junction complex downstream of premature translation termination codon.

Authors:  Hyung Chul Lee; Nara Oh; Hana Cho; Junho Choe; Yoon Ki Kim
Journal:  FEBS Lett       Date:  2010-01-12       Impact factor: 4.124

2.  PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C.

Authors:  T Goldmann; N Overlack; U Wolfrum; K Nagel-Wolfrum
Journal:  Hum Gene Ther       Date:  2011-03-25       Impact factor: 5.695

Review 3.  Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Authors:  R Kohan; I A Cismondi; A M Oller-Ramirez; N Guelbert; Tapia V Anzolini; G Alonso; S E Mole; Dodelson R de Kremer; Noher I de Halac
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

4.  Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis.

Authors:  Lenka Nosková; Viktor Stránecký; Hana Hartmannová; Anna Přistoupilová; Veronika Barešová; Robert Ivánek; Helena Hůlková; Helena Jahnová; Julie van der Zee; John F Staropoli; Katherine B Sims; Jaana Tyynelä; Christine Van Broeckhoven; Peter C G Nijssen; Sara E Mole; Milan Elleder; Stanislav Kmoch
Journal:  Am J Hum Genet       Date:  2011-08-04       Impact factor: 11.025

Review 5.  Nonsense-mediated mRNA decay (NMD) in animal embryogenesis: to die or not to die, that is the question.

Authors:  Jungwook Hwang; Lynne E Maquat
Journal:  Curr Opin Genet Dev       Date:  2011-08       Impact factor: 5.578

6.  The crystal structure of palmitoyl protein thioesterase 1 and the molecular basis of infantile neuronal ceroid lipofuscinosis.

Authors:  J J Bellizzi; J Widom; C Kemp; J Y Lu; A K Das; S L Hofmann; J Clardy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

7.  Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6.

Authors:  Todor Arsov; Katherine R Smith; John Damiano; Silvana Franceschetti; Laura Canafoglia; Catherine J Bromhead; Eva Andermann; Danya F Vears; Patrick Cossette; Sulekha Rajagopalan; Alan McDougall; Vito Sofia; Michael Farrell; Umberto Aguglia; Andrea Zini; Stefano Meletti; Michela Morbin; Saul Mullen; Frederick Andermann; Sara E Mole; Melanie Bahlo; Samuel F Berkovic
Journal:  Am J Hum Genet       Date:  2011-05-05       Impact factor: 11.025

Review 8.  Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).

Authors:  Richard S Finkel
Journal:  J Child Neurol       Date:  2010-06-02       Impact factor: 1.987

9.  UPF1 association with the cap-binding protein, CBP80, promotes nonsense-mediated mRNA decay at two distinct steps.

Authors:  Jungwook Hwang; Hanae Sato; Yalan Tang; Daiki Matsuda; Lynne E Maquat
Journal:  Mol Cell       Date:  2010-08-05       Impact factor: 17.970

Review 10.  Gene therapy for lysosomal storage diseases.

Authors:  Mark S Sands; Beverly L Davidson
Journal:  Mol Ther       Date:  2006-03-20       Impact factor: 11.454

View more
  23 in total

1.  Antigen presenting cell abnormalities in the Cln3(-/-) mouse model of juvenile neuronal ceroid lipofuscinosis.

Authors:  Samantha L Hersrud; Attila D Kovács; David A Pearce
Journal:  Biochim Biophys Acta       Date:  2016-04-19

2.  Clinical and molecular characterization of non-syndromic retinal dystrophy due to c.175G>A mutation in ceroid lipofuscinosis neuronal 3 (CLN3).

Authors:  Fred K Chen; Xiao Zhang; Jonathan Eintracht; Dan Zhang; Sukanya Arunachalam; Jennifer A Thompson; Enid Chelva; Dominic Mallon; Shang-Chih Chen; Terri McLaren; Tina Lamey; John De Roach; Samuel McLenachan
Journal:  Doc Ophthalmol       Date:  2018-11-16       Impact factor: 2.379

Review 3.  NMD: At the crossroads between translation termination and ribosome recycling.

Authors:  Alper Celik; Stephanie Kervestin; Allan Jacobson
Journal:  Biochimie       Date:  2014-11-13       Impact factor: 4.079

4.  Detailed Clinical Phenotype and Molecular Genetic Findings in CLN3-Associated Isolated Retinal Degeneration.

Authors:  Cristy A Ku; Sarah Hull; Gavin Arno; Ajoy Vincent; Keren Carss; Robert Kayton; Douglas Weeks; Glenn W Anderson; Ryan Geraets; Camille Parker; David A Pearce; Michel Michaelides; Robert E MacLaren; Anthony G Robson; Graham E Holder; Elise Heon; F Lucy Raymond; Anthony T Moore; Andrew R Webster; Mark E Pennesi
Journal:  JAMA Ophthalmol       Date:  2017-07-01       Impact factor: 7.389

Review 5.  Nonsense-mediated decay in genetic disease: friend or foe?

Authors:  Jake N Miller; David A Pearce
Journal:  Mutat Res Rev Mutat Res       Date:  2014-05-28       Impact factor: 5.657

Review 6.  Lysosomal storage diseases--the horizon expands.

Authors:  Rose-Mary Naaman Boustany
Journal:  Nat Rev Neurol       Date:  2013-08-13       Impact factor: 42.937

7.  Is myopathy with rimmed vacuoles a hallmark of juvenile neuronal ceroid lipofuscinosis (CLN3)?

Authors:  Eugenia Borgione; Filippa Castello; Mariangela Lo Giudice; Sandro Santa Paola; Simona Salvatore; Gianna Berti; Alessandro Malandrini; Maria Bottitta; Sebastiano Antonino Musumeci; Carmela Scuderi
Journal:  Neurol Sci       Date:  2015-12-23       Impact factor: 3.307

8.  The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy.

Authors:  Jake N Miller; Attila D Kovács; David A Pearce
Journal:  Hum Mol Genet       Date:  2014-09-08       Impact factor: 6.150

Review 9.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

10.  Progressive retinal degeneration and glial activation in the CLN6 (nclf) mouse model of neuronal ceroid lipofuscinosis: a beneficial effect of DHA and curcumin supplementation.

Authors:  Myriam Mirza; Cornelia Volz; Marcus Karlstetter; Monica Langiu; Aleksandra Somogyi; Mika O Ruonala; Ernst R Tamm; Herbert Jägle; Thomas Langmann
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.